19 May 2013
Keywords: novartis, files, glivec, gist, japan, switzerland, filed
Article | 03 February 2003
Switzerland's Novartis has filed for approval to market Glivec(imatinib) in the treatment of gastrointestinal stromal tumors in Japan.
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 February 2003
17 May 2013
© 2013 thepharmaletter.com